On May 16, 2021 Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncology, reported ATG-101, a novel PD-L1/4-1BB bispecific antibody being developed by the company, has completed its quantitative and systems pharmacology (QSP) modeling that will provide data guiding the first-in-human study of ATG-101 (Press release, Antengene, MAY 16, 2021, View Source [SID1234580077]). Antengene plans to submit a clinical trial application for the first-in-human (FIH) study of ATG-101 in Australia starting in mid-2021, to be followed by submissions in US and China.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
QSP is a highly innovative methodology that has been used recently in drug discovery and development. QSP supports the pharmacological research of drugs through modeling and simulations, and quantitatively determines drug pharmacology and dynamical properties through integrated pharmacokinetics (PK), pharmacodynamics (PD), and statistical modeling, in providing evidential support to the design, decision-making, and dose selection in clinical trials1. In December 2020, Antengene entered into a strategic collaboration with Applied BioMath, LLC to initiate the pharmacology modeling of ATG-101 to determine the starting and efficacious doses for the first-in-human study of the drug candidate. Completing this QSP modeling will deepen our understanding of ATG-101’s antitumor mechanism and provide us with the quality data that will enhance the first-in-human study of ATG-101.
"We collaborated with Applied BioMath to best prepare our team for predicting accurate starting and efficacious doses for our first-in-human studies of ATG-101," said Dirk Hoenemann, M.D., VP, Head of Medical Affairs for Asia Pacific Region (APAC) and Early Clinical Development. "The Applied BioMath models provided us with a thorough understanding of ATG-101’s antitumor mechanism which enabled us to better design clinical trials moving forward, including our first-in-human trials."
"Systems pharmacology modeling is uniquely suited for the translation of antibody therapies from in vivo experiments to first-in-human studies," said Dr. John Burke, PhD, Co-Founder, President, and CEO of Applied BioMath. "Complicated mechanism of actions, as is common in modern antibody therapy designs, requires more sophisticated translational approaches than traditional methods and systems pharmacology has a proven track record of providing accurate translation for such therapies."
To date, Antengene has achieved multiple progress with the development of ATG-101, and is actively preparing to initiate clinical trials of ATG-101 in multiple countries and regions, including China, Australia, and the U.S. In China, Antengene has previously entered into a partnership with Wuxi Biologics for the chemistry, manufacturing, and control (CMC) manufacturing of ATG-101 to further optimize and accelerate the development of ATG-101.
About ATG-101
ATG-101 is a novel PD-L1/4-1BB bi-specific antibody being developed for the treatment of cancer. ATG-101 can activate anti-tumor immune effectors by simultaneously blocking PD-L1/PD-1 binding and 4-1BB stimulation. In the presence of PD-L1 over-expressed cancer cells, ATG-101 showed a significant and PD-L1 crosslinking-dependent 4-1BB agonist activity, thus enhancing therapeutic efficacy, and mitigating hepatoxicity simultaneously. ATG-101 demonstrated potent activity in preclinical animal models, including strong tumor-suppressing effect in models of PD-1/PD-L1 inhibitor-resistant or -relapsed tumors. Meanwhile, the GLP toxicology study has produced results highlighting a favorable safety profile.
At present, Antengene has already completed the preclinical study of ATG-101, and is actively preparing to initiate clinical trials of ATG-101 in multiple countries and regions, including China, Australia, and the U.S. Antengene plans to submit a clinical trial application for the first-in-human (FIH) study of ATG-101 in Australia starting in mid-2021, to be followed by submissions in U.S. and China.